Announcements Trials
Browse Landscape

Phase

Phase 3 9Phase 4 3Phase 1 3Phase 2 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 10INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Conditions

Arthritis, Rheumatoid 3

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × Adalimumab × Clear all
NCT02092467 2021-08-17

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

Pfizer

Phase 4 Completed
4,372 enrolled 22 charts

Arthritis, Rheumatoid

NCT01283971 2014-02-10

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor

Hoffmann-La Roche

Phase 4 Terminated
96 enrolled 27 charts

Arthritis, Rheumatoid

NCT00420927 2012-04-18

OPTIMA

Abbott

Phase 4 Completed
1,032 enrolled 25 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡